The neoadjuvant chemotherapy setting is applied to some patients with locally advanced breast cancer to facilitate breast conservation during surgery and can provide important prognostic information about the response to treatment, particularly in HER2-positive breast cancer and TNBC [7]. The gene discussed is ERBB2; the disease is breast cancer.